Replies to post #102844 on Biotech Values

[EyeamBill]

SNY: No Inclusion of 4% Reduction In Guidance

Dew, is it safe to say then that SNY does have a floor that it cannot fall through for enoxaparin pricing lest they run the risk of another PR for reduced guidance or missing their previous guidance?

Bill